Utah's new verification system for its healthcare AI sandbox reflects a distinct state-level regulatory approach, part of an increasingly fragmented patchwork of state and federal health AI oversight.
Confido Health's $12.5 million extension targets AI for medical practice operations, a less flashy but steadily funded corner of health AI focused on scheduling, billing and administrative efficiency.
HHS's four new ARPA-H initiatives aim to use AI to fix clinical trials' chronic bottlenecks, from slow patient matching to limited research-site capacity, though rigorous evidence of AI's trial benefits remains thin.
Anthropic is joining a federal clinical AI initiative run by ARPA-H and plans a closed-door health care event, a notable expansion into medicine for a company that has repeatedly warned the public about AI's catastrophic risks.
Diligent Robotics is adapting its hospital delivery robot Moxi for senior living facilities, testing whether AI-driven supply runs and resident assistance can help operators cope with persistent labor shortages.
A meta-analysis of 16 studies in JMIR Mental Health finds wearable AI models detect existing depression with up to 96% accuracy, but the same technology performs far worse at predicting future depressive episodes, raising questions about real-world readiness.
GE HealthCare and Mass General Brigham announced a research collaboration on September 23, 2026 to explore generative AI that helps radiation oncology teams navigate scattered treatment records. The project builds on earlier MGH software that GE says cut treatment start times from 30 days to eight at one hospital.
Rome's Sant'Andrea University Hospital routed nearly 5,700 emergency ECGs through Powerful Medical's Queen of Hearts AI over six months, catching STEMI-equivalent heart attacks that standard criteria often miss and alerting cardiologists in under 17 seconds. The case study, released October 7, 2026, comes as the AI also gains FDA authorization and expands into prehospital ambulance care.
UpDoc has announced FDA clearance for software that gives type 2 diabetes patients insulin dosing instructions through a conversational interface, a device the FDA record shows was cleared in December 2025 as a bounded, physician-configured insulin calculator rather than an autonomous AI doctor.
Medidata's second annual survey of pharmaceutical trial sponsors found experienced AI adopters report faster timelines and fewer protocol deviations, but most of the industry says AI has yet to meet expectations, with gains so far concentrated in routine administrative workflows.